PAR and the BML findings, page-25

You asked, and so did I. The answer:

"As an AI language model, I do not have access to privileged information or the ability to predict the future actions of Paradigm Biopharmaceuticals or other companies. It is ultimately up to Paradigm Biopharmaceuticals and any potential partners to decide when and if they wish to enter into a partnership deal."

"However, it is common for biopharmaceutical companies to enter into partnership agreements with other companies or organizations to help fund and accelerate the development of their drug candidates, as well as to gain access to expertise, resources, and distribution channels."

"If Paradigm Biopharmaceuticals continues to demonstrate promising results in their clinical trials, it is possible that they may attract the interest of potential partners who are looking to expand their portfolios in the areas of inflammatory and orphan diseases."